Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00718809 · ClinicalTrials.gov registry record · Phase 2
Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00718809: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00718809 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00718809, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This phase II trial is studying how well saracatinib works in treating patients with relapsed or refractory thymoma or thymic cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Interventions
- DRUG saracatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00718809
The ClinicalTrials.gov registry entry for NCT00718809 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which saracatinib is the first listed.
NCT00718809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00718809 about?
NCT00718809 is a clinical study titled "Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer". This phase II trial is studying how well saracatinib works in treating patients with relapsed or refractory thymoma or thymic cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
What is the current status of trial NCT00718809?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2008-06. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00718809?
The interventions under investigation include: saracatinib (DRUG).
Who is sponsoring clinical trial NCT00718809?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.